Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid.
about
Biophysical characterization of α-synuclein and its controversial structureMicrotubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filamentsBiochemical characterization of the core structure of alpha-synuclein filaments.Defining the substrate specificity determinants recognized by the active site of C-terminal Src kinase-homologous kinase (CHK) and identification of β-synuclein as a potential CHK physiological substrate.The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease.CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementiaRegion-specific protein abundance changes in the brain of MPTP-induced Parkinson's disease mouse modelNeuropathology of synuclein aggregates.Abnormal neurites containing C-terminally truncated alpha-synuclein are present in Alzheimer's disease without conventional Lewy body pathology.Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy.Characterization of presenilin complexes from mouse and human brain using Blue Native gel electrophoresis reveals high expression in embryonic brain and minimal change in complex mobility with pathogenic presenilin mutations.Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathologyUse of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders.Lack of alpha-synuclein increases amyloid plaque accumulation in a transgenic mouse model of Alzheimer's disease.Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse modelCould a loss of alpha-synuclein function put dopaminergic neurons at risk?The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.Alpha-synuclein dysfunction in Lewy body diseases.Determining composition of micron-scale protein deposits in neurodegenerative disease by spatially targeted optical microproteomics.Restoration of intestinal function in an MPTP model of Parkinson's Disease.Role of synucleins in Alzheimer's disease.Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.Modulation of alpha-synuclein aggregation by dopamine: a review.Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies.The Synucleinopathies: Twenty Years On.Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyondAn antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology.Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein.Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains.Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivoRole of neurotoxicants and traumatic brain injury in α-synuclein protein misfolding and aggregation.Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease.Novel 'inflammatory plaque' pathology in presenilin-1 Alzheimer's disease.Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner.The role of NAC in amyloidogenesis in Alzheimer's disease.α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment.Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats.Dopamine D2 receptor knockout mice develop features of Parkinson disease.Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins.
P2860
Q26828504-B0EA83C0-63FC-40CB-9BA9-BCAD345470E1Q28141728-03077A33-82B4-4F59-B403-AB47527CDC38Q30827075-D1FD2B40-5260-4C19-A4F9-9B133AA69786Q31019452-F6922797-9E96-448C-B3A8-5C8B15034EEDQ31807516-D39283E2-E044-4418-94B7-F011B6580377Q33239180-463F3CEF-78B6-4D1C-A1D6-25385C35E4E0Q33810589-41DFB757-D9B3-41A1-83E2-FE9C35B7E395Q33957376-F888BAC6-0DAB-4A95-ACEB-8636E9F1135AQ34358218-F189A628-8A69-4EB8-B24F-8F25A77AAC76Q34491408-3D2651FF-1E39-43D9-87E6-90A41D17E882Q34649271-87F03909-5F56-4F82-98D3-468C0DA139C4Q34657526-4F4B28F7-E704-4CE5-9388-A9DAE12328ECQ35597118-145868CD-6392-4E40-9B30-6C5E5AA5D98FQ35699583-49956BAA-7B52-4C28-A47C-BEDEEBA78EB3Q35747138-8B5AF9D9-584D-44F3-A82B-693B657ACEC5Q35800096-F6B3ECAA-B2FE-4476-BBF8-A695CB41D3BAQ35894167-2BCC0CB5-9FB4-4D38-A29F-C9109A14C64DQ36224224-C438FA18-F31D-400F-9649-63A27293479FQ36242304-9F91D9D7-C7AF-41B7-B9AF-8E87E5211FFAQ37137476-7218B152-F8E3-409D-AA0E-C12EFB04C032Q37306581-E5788CB0-8F2D-400F-A0F6-B4B26785E712Q37320252-48630333-2666-46B9-B19A-30DD7139DD0BQ37483616-6B423FA3-4D44-41D7-B852-C65575AB9985Q37691087-61A74995-30BB-4287-9FC1-C9EA33FC0A55Q37693375-BF4A9080-D4DF-4AFF-95E1-E3D09E349083Q38363786-55B59A20-B8A3-4FBD-990E-FCB1F91AEF60Q38405069-6F5E6D29-8468-4D88-8557-75436E8C3FDFQ38669105-8F761A43-CD4F-43B6-9AC9-7E124509797CQ38819135-415F5389-FAA6-4A22-9DB0-F3F79FA2479CQ38966914-A25A2C7C-8C96-4DED-8811-BACE9CBDC713Q39043644-3D2559B2-5D04-4712-AC59-FAAFB770CB2CQ40017984-491FCE44-65BE-4F3E-83AB-680527C55236Q40390704-908E8159-7994-4A3F-9BD1-9AF947A8FD0FQ42409261-E89AFE18-DE1B-4AD7-9752-A5534898371DQ42857209-2447E956-0DC8-410C-85C2-E243D400669AQ43065145-42222C09-731D-4AF0-8884-46C156112482Q43244813-DF0E423F-9931-43F7-A3C4-2367FE22962BQ43247253-6F11D02C-0A22-4B6D-B677-7B65E9CA4774Q43256881-190E9CF8-51B7-4A70-80BD-25963D5490BAQ43735119-6E7302A7-457C-4EBA-8588-ED8F3C397856
P2860
Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Non-Abeta component of Alzheim ...... associated with Abeta amyloid.
@ast
Non-Abeta component of Alzheim ...... associated with Abeta amyloid.
@en
type
label
Non-Abeta component of Alzheim ...... associated with Abeta amyloid.
@ast
Non-Abeta component of Alzheim ...... associated with Abeta amyloid.
@en
prefLabel
Non-Abeta component of Alzheim ...... associated with Abeta amyloid.
@ast
Non-Abeta component of Alzheim ...... associated with Abeta amyloid.
@en
P2093
P2860
P1476
Non-Abeta component of Alzheim ...... associated with Abeta amyloid
@en
P2093
B C Campbell
C A McLean
C L Masters
J G Culvenor
K Beyreuther
P2860
P304
P356
10.1016/S0002-9440(10)65220-0
P407
P577
1999-10-01T00:00:00Z